《Nature,6月9日,Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-06-10
  • Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic

    Rodrigo Jácome, José Alberto Campillo-Balderas, Samuel Ponce de León, Arturo Becerra & Antonio Lazcano

    Scientific Reports volume 10, Article number: 9294 (2020)

    Abstract

    As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter. Moreover, a multiple alignment of several SARS-CoV-2, SARS and MERS-related coronaviruses polymerases shows that these residues are conserved in all these viruses, opening the possibility to use sofosbuvir against these highly infectious pathogens.

  • 原文来源:https://www.nature.com/articles/s41598-020-66440-9
相关报告
  • 《6月9日_索非布韦是一种治疗SARS-CoV-2感染的潜在药物》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-06-10
    • 信息名称:索非布韦是一种治疗SARS-CoV-2感染的潜在药物 1.时间:2020年6月9日 2.机构或团队:墨西哥国立自治大学 3.事件概要: 墨西哥国立自治大学于6月9日在Scientific Reports上发表题为“Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic”的文章。文章指出,截至目前,还没有治疗SARS-CoV-2感染的抗病毒药物,开发疫苗可能需要几个月甚至几年的时间。与索非布韦(一种批准用于丙型肝炎病毒感染的核苷类似物抗病毒药物)结合的丙型肝炎病毒聚合酶与SARS-CoV聚合酶的结构叠加表明,后者中存在与药物结合的残基。此外,对几种SARS-CoV-2、SARS和MERS相关的冠状病毒聚合酶进行多重比对表明,这些残基在所有这些病毒中都是保守的,这为使用索非布韦对抗这些高传染性病原体提供了可能。 4.附件: 原文链接: https://www.nature.com/articles/s41598-020-66440-9
  • 《Nature,6月9日,Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-06-10
    • Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 Brandi N. Williamson, Friederike Feldmann, Benjamin Schwarz, Kimberly Meade-White, Danielle P. Porter, Jonathan Schulz, Neeltje van Doremalen, Ian Leighton, Claude Kwe Yinda, Lizzette Pérez-Pérez, Atsushi Okumura, Jamie Lovaglio, Patrick W. Hanley, Greg Saturday, Catharine M. Bosio, Sarah Anzick, Kent Barbian, Tomas Cihlar, Craig Martens, Dana P. Scott, Vincent J. Munster & Emmie de Wit Nature (2020) Abstract Effective therapeutics to treat COVID-19 are urgently needed. While many investigational, approved, and repurposed drugs have been suggested, preclinical data from animal models can guide the search for effective treatments by ruling out treatments without in vivo efficacy. Remdesivir (GS-5734) is a nucleotide analog prodrug with broad antiviral activity1,2, that is currently investigated in COVID-19 clinical trials and recently received Emergency Use Authorization from the US Food and Drug Administration3,4. In animal models, remdesivir treatment was effective against MERS-CoV and SARS-CoV infection.2,5,6 In vitro, remdesivir inhibited replication of SARS-CoV-2.7,8 Here, we investigated the efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection9. In contrast to vehicle-treated animals, animals treated with remdesivir did not show signs of respiratory disease and had reduced pulmonary infiltrates on radiographs and reduced virus titers in bronchoalveolar lavages 12hrs after the first treatment administration. Virus shedding from the upper respiratory tract was not reduced by remdesivir treatment.